Hims & Hers Scales Platform-Led Digital Healthcare Access and Care

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates at the intersection of healthcare and proprietary technology by positioning its digital platform as the core engine of care delivery rather than a simple telehealth interface. The company has built an end-to-end, vertically integrated ecosystem that connects consumers, licensed providers, diagnostics, pharmacy fulfillment and ongoing care management within a single technology-driven experience. HIMS’ platform is designed to continuously learn from patient interactions, enabling more personalized, proactive and adaptive treatment pathways over time.

Recent developments highlight how this technology foundation is being expanded. Hims & Hers has rolled out new specialties, including menopause and perimenopause care, low testosterone treatments and advanced weight management offerings, all supported by integrated at-home lab testing and digital monitoring. The launch of comprehensive lab diagnostics marks a key evolution, allowing the platform to move beyond treating known conditions toward identifying risks earlier and guiding preventative care. Strategic investments in AI, data infrastructure and proprietary compounding and manufacturing capabilities further strengthen the platform’s ability to translate health data into tailored action at scale.

Together, these initiatives reinforce Hims & Hers’ positioning as a technology-led healthcare platform, where software, data and vertical integration are central to expanding access, improving outcomes and supporting long-term, personalized health management.

TEM & LFMD’s Technology-Driven Healthcare Platforms

Tempus AI, Inc. TEM exemplifies how healthcare companies are increasingly built around proprietary technology platforms rather than standalone services. Tempus AI integrates AI, machine learning and multimodal clinical data into a unified operating system that supports physicians, researchers and life sciences partners. Recent developments reinforce this positioning as TEM expanded its AI-driven diagnostics with FDA clearances for updated imaging and RNA sequencing tools, while Tempus AI also deepened hospital and research collaborations to embed its platform directly into clinical workflows. Collectively, Tempus AI leverages technology to translate complex data into actionable, precision-care insights.

LifeMD, Inc. LFMD operates squarely at the intersection of healthcare and proprietary technology by anchoring its virtual care model on a vertically integrated digital platform. LifeMD combines telehealth, diagnostics, pharmacy fulfillment and care coordination into a single technology-enabled experience designed to support long-term patient relationships. Recent developments reinforce this strategy as LFMD sharpened its focus into a pure-play virtual care and pharmacy platform and expanded its technology-led weight management offerings. Through these initiatives, LifeMD continues to use its proprietary platform to scale access, streamline care delivery and deepen patient engagement across multiple clinical categories.

Zacks Names #1 Semiconductor Stock

This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.

With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research